Table 1 Baseline characteristics of studies included in the NMA. PD-1: programmed death receptor 1 inhibitors; TP: Paclitaxel plus cis-platinum; FP: fluorouracil plus cis-platinum
Study(year) | Author | Randomized patients | Histology | Regimen | Area |
|---|---|---|---|---|---|
KEYNOTE 590 (2019) | Sun JM | 274 | squamous | PD1 + FP | GLOBLE |
274 | squamous | FP | GLOBLE | ||
ESCORT-1st (2021) | Luo H | 298 | squamous | PD1 + TP | CHINA |
298 | squamous | TP | CHINA | ||
CHECKMATE 648 (2022) | Doki Y | 321 | squamous | PD1 + FP | GLOBLE |
324 | squamous | FP | GLOBLE | ||
JUPITER 06 (2022) | Wang ZX | 257 | squamous | PD1 + TP | CHINA |
257 | squamous | TP | CHINA | ||
ORIENT 15 (2022) | Lu Z | 327 | squamous | PD1 + TP | GLOBLE |
332 | squamous | TP | GLOBLE | ||
TP vs FP (2016) | Liu Y | 195 | squamous | TP | CHINA |
203 | squamous | FP | CHINA |